Across TCGA pan-cancer cohorts, AGAP6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AGAP6 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher AGAP6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGAP6 expression acts as an unfavorable survival marker.
STAD, HNSC, and SARC are the cancer types where AGAP6 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.